BPG is committed to discovery and dissemination of knowledge
Articles Published Processes
9/15/2014 5:09:00 PM | Browse: 1279 | Download: 1065
 |
Received |
|
2013-03-21 11:11 |
 |
Peer-Review Started |
|
2013-03-21 12:52 |
 |
To Make the First Decision |
|
2013-04-16 09:02 |
 |
Return for Revision |
|
2013-04-17 10:09 |
 |
Revised |
|
|
 |
Second Decision |
|
2013-06-03 16:06 |
 |
Accepted by Journal Editor-in-Chief |
|
|
 |
Accepted by Executive Editor-in-Chief |
|
2013-06-04 09:40 |
 |
Articles in Press |
|
|
 |
Publication Fee Transferred |
|
|
 |
Edit the Manuscript by Language Editor |
|
|
 |
Typeset the Manuscript |
|
2013-06-09 13:10 |
 |
Publish the Manuscript Online |
|
2013-06-20 00:12 |
Category |
Rheumatology |
Manuscript Type |
Editorial |
Article Title |
B cell depletion in scleroderma lung disease: A promising new treatment?
|
Manuscript Source |
Invited Manuscript |
All Author List |
Dimitrios Daoussis and Andrew P Andonopoulos |
Funding Agency and Grant Number |
|
Corresponding Author |
Dr. Dimitrios Daoussis, MD, Division of Rheumatology, Department of Internal Medicine, Patras University Hospital, University of Patras Medical School, Rion, 26504 Patras, Greece. jimdaoussis@hotmail.com
|
Key Words |
Rituximab; Scleroderma; Systemic sclerosis; Interstitial lung disease; Treatment |
Core Tip |
Rituximab (RTX) may be an effective treatment for systemic sclerosis (SSc)-associated interstitial lung disease (ILD). A large scale study assessing the efficacy of RTX in SSc associated ILD is warranted. If RTX turns out to be effective, it would be a major therapeutic advance in SSc since it can be administered on a long term basis due to its acceptable safety profile. |
Publish Date |
2013-06-20 00:12 |
Citation |
Daoussis D, Andonopoulos AP. B cell depletion in scleroderma lung disease: A promising new treatment? World J Rheumatol 2013; 3(2): 9-11 |
URL |
http://www.wjgnet.com/2220-3214/full/v3/i2/9.htm |
DOI |
http://dx.doi.org/10.5499/wjr.v3.i2.9 |
© 2004-2025 Baishideng Publishing Group Inc. All rights reserved. 7041 Koll Center Parkway, Suite 160, Pleasanton, CA 94566, USA
California Corporate Number: 3537345